
1. PLoS One. 2014 Mar 28;9(3):e92747. doi: 10.1371/journal.pone.0092747. eCollection
2014.

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2
infected patients failing a raltegravir-containing regimen.

Cavaco-Silva J(1), Abecasis A(2), Miranda AC(3), Poças J(4), Narciso J(5), Águas 
MJ(6), Maltez F(7), Almeida I(8), Germano I(9), Diniz A(10), Gonçalves Mde F(11),
Gomes P(12), Cunha C(1), Camacho RJ(13); Portuguese HIV-2 Resistance Study Group.

Collaborators: Miranda AC, Mineiro A, Diniz A, Santos C, Vasconcelos C, Guerreiro
C, Faria D, Valadas E, Teófilo E, Lampreia F, Roxo F, Maltez F, Gomes F, Antunes 
F, Amaro G, Pinto IV, Almeida I, Germano I, Neves I, Sá J, Machado J, Narciso J, 
Bernardo JL, Poças J, Vera J, Mansinho K, Rosado L, Duque L, Tavares L, Jesus MB,
Águas MJ, Aleixo MJ, Faria N, Janeiro N, Brito P, Fonseca P, Proença P, Abreu R, 
Faria T, Branco T, Caixas U.

Author information: 
(1)Centro de Malária e Outras Doenças Tropicais, Unidade de Microbiologia Médica,
Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa,
Portugal.
(2)Centro de Malária e Outras Doenças Tropicais, Unidade de Saúde Pública
Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical,
Universidade Nova de Lisboa, Lisboa, Portugal.
(3)Serviço de Doenças Infecciosas, Centro Hospitalar de Lisboa Ocidental, Lisboa,
Portugal.
(4)Hospital de São Bernardo, Centro Hospitalar de Setúbal, Setúbal, Portugal.
(5)Hospital dos SAMS, Lisboa, Portugal.
(6)Hospital Garcia de Orta, Almada, Portugal.
(7)Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisboa, Portugal.
(8)Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal.
(9)Hospital de São José, Centro Hospitalar de Lisboa Central, Lisboa, Portugal.
(10)Hospital Pulido Valente, Centro Hospitalar de Lisboa Norte, Lisboa, Portugal.
(11)Laboratório de Microbiologia Clínica e Biologia Molecular, Serviço de
Patologia Clínica (SPC), Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.
(12)Laboratório de Microbiologia Clínica e Biologia Molecular, Serviço de
Patologia Clínica (SPC), Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal;
Centro de Malária e Outras Doenças Tropicais, Instituto de Higiene e Medicina
Tropical, Universidade Nova de Lisboa, Lisboa, Portugal; Centro de Investigação
Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Sul,
Caparica, Portugal.
(13)Centro de Malária e Outras Doenças Tropicais, Instituto de Higiene e Medicina
Tropical, Universidade Nova de Lisboa, Lisboa, Portugal; Rega Institute for
Medical Research, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium.

To characterize the HIV-2 integrase gene polymorphisms and the pathways to
resistance of HIV-2 patients failing a raltegravir-containing regimen, we studied
63 integrase strand transfer inhibitors (INSTI)-naïve patients, and 10 heavily
pretreated patients exhibiting virological failure while receiving a salvage
raltegravir-containing regimen. All patients were infected by HIV-2 group A.
61.4% of the integrase residues were conserved, including the catalytic motif
residues. No INSTI-major resistance mutations were detected in the virus
population from naïve patients, but two amino acids that are secondary resistance
mutations to INSTIs in HIV-1 were observed. The 10 raltegravir-experienced
patients exhibited resistance mutations via three main genetic pathways: N155H,
Q148R, and eventually E92Q - T97A. The 155 pathway was preferentially used (7/10 
patients). Other mutations associated to raltegravir resistance in HIV-1 were
also observed in our HIV-2 population (V151I and D232N), along with several novel
mutations previously unreported. Data retrieved from this study should help build
a more robust HIV-2-specific algorithm for the genotypic interpretation of
raltegravir resistance, and contribute to improve the clinical monitoring of
HIV-2-infected patients.

DOI: 10.1371/journal.pone.0092747 
PMCID: PMC3969368
PMID: 24681625  [Indexed for MEDLINE]

